hydroxychloroquine has been researched along with Body Weight in 17 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, randomized trial of orally administered hydroxychloroquine sulphate in the prevention of venous thromboembolism after elective surgery on the hip, the drug or a placebo was given to fifty consecutive patients." | 9.04 | Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. ( Ainsworth, ME; Bowcock, SA; Cooke, ED; Dawson, MH; Ibbotson, RM; Pilcher, MF, 1977) |
| " No previous studies have assessed abnormal weight gain as a putative side effect of long-term doxycycline treatment; thus, the objective of the present study was to characterize this phenomenon." | 5.40 | Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. ( Angelakis, E; Armougom, F; Giorgi, R; Kankoe, S; Lagier, JC; Million, M; Raoult, D, 2014) |
| "Chloroquine and hydroxychloroquine effectively suppress rheumatoid arthritis with a superior benefit to risk ratio." | 5.05 | Antimalarial drugs for rheumatoid arthritis. ( Mackenzie, AH, 1983) |
| "In a double-blind, randomized trial of orally administered hydroxychloroquine sulphate in the prevention of venous thromboembolism after elective surgery on the hip, the drug or a placebo was given to fifty consecutive patients." | 5.04 | Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. ( Ainsworth, ME; Bowcock, SA; Cooke, ED; Dawson, MH; Ibbotson, RM; Pilcher, MF, 1977) |
| "Analysis of all published cases and Food and Drug Administration (FDA) reports of retinopathy attributed to hydroxychloroquine sulfate (Plaquenil) does not reveal any evidence of permanent visual field scotoma occurring when the daily dose is related to body weight and does not exceed 6." | 4.78 | Ocular safety of hydroxychloroquine sulfate (Plaquenil). ( Bernstein, HN, 1992) |
| "Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing." | 3.88 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. ( Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018) |
| " Study results indicated that HCQ dosing management was adequate based on the revised guidelines." | 1.91 | Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus. ( Jung, SY; Kim, YJ; Lee, JE; Nam, DR; Sung, YK, 2023) |
| "Hydroxychloroquine (HCQ) is an effective treatment for patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) and has been used for these patients in more than 70 nations." | 1.43 | Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. ( Morita, S; Takahashi, T; Yokota, N; Yoshida, Y, 2016) |
| " No previous studies have assessed abnormal weight gain as a putative side effect of long-term doxycycline treatment; thus, the objective of the present study was to characterize this phenomenon." | 1.40 | Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. ( Angelakis, E; Armougom, F; Giorgi, R; Kankoe, S; Lagier, JC; Million, M; Raoult, D, 2014) |
| "To reassess the prevalence of and risk factors for hydroxychloroquine retinal toxicity and to determine dosage levels that facilitate safe use of the drug." | 1.40 | The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. ( Marmor, MF; Melles, RB, 2014) |
| " I therefore consider these dosage rates safe, since they are below the threshold of retinal toxicity." | 1.27 | Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. ( Mackenzie, AH, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JE | 1 |
| Nam, DR | 1 |
| Sung, YK | 1 |
| Kim, YJ | 1 |
| Jung, SY | 1 |
| Donia, T | 1 |
| Gerges, MN | 1 |
| Mohamed, TM | 1 |
| Jorge, AM | 1 |
| Melles, RB | 2 |
| Zhang, Y | 1 |
| Lu, N | 1 |
| Rai, SK | 1 |
| Young, LH | 1 |
| Costenbader, KH | 1 |
| Ramsey-Goldman, R | 1 |
| Lim, SS | 1 |
| Esdaile, JM | 1 |
| Clarke, AE | 1 |
| Urowitz, MB | 1 |
| Askanase, A | 1 |
| Aranow, C | 1 |
| Petri, M | 2 |
| Choi, H | 1 |
| Angelakis, E | 1 |
| Million, M | 1 |
| Kankoe, S | 1 |
| Lagier, JC | 1 |
| Armougom, F | 1 |
| Giorgi, R | 1 |
| Raoult, D | 1 |
| Marmor, MF | 1 |
| Li, CL | 1 |
| He, J | 1 |
| Li, ZG | 1 |
| Zheng, LW | 1 |
| Hua, H | 1 |
| Morita, S | 1 |
| Takahashi, T | 1 |
| Yoshida, Y | 1 |
| Yokota, N | 1 |
| Furlong, HC | 1 |
| Wessels, JM | 1 |
| Guerra, MT | 1 |
| Stämpfli, MR | 1 |
| Foster, WG | 1 |
| Easterbrook, M | 1 |
| Wang, Y | 1 |
| Yan, T | 1 |
| Shen, J | 1 |
| Guo, H | 1 |
| Xiang, X | 1 |
| Mackenzie, AH | 2 |
| Lakatta, C | 1 |
| Magder, L | 1 |
| Goldman, D | 1 |
| Cooke, ED | 1 |
| Dawson, MH | 1 |
| Ibbotson, RM | 1 |
| Bowcock, SA | 1 |
| Ainsworth, ME | 1 |
| Pilcher, MF | 1 |
| Bernstein, HN | 1 |
| Mueller, MN | 1 |
| Mallinson, CN | 1 |
| Candy, JC | 1 |
| Cowan, R | 1 |
| Prior, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [NCT00005436] | 0 participants | Observational | 1991-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
1 review available for hydroxychloroquine and Body Weight
| Article | Year |
|---|---|
Ocular safety of hydroxychloroquine sulfate (Plaquenil).
Topics: Body Weight; Humans; Hydroxychloroquine; Retinitis Pigmentosa; Risk Factors | 1992 |
2 trials available for hydroxychloroquine and Body Weight
| Article | Year |
|---|---|
Antimalarial drugs for rheumatoid arthritis.
Topics: Amodiaquine; Antimalarials; Arthritis, Rheumatoid; Body Weight; Chloroquine; Clinical Trials as Topi | 1983 |
Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations.
Topics: Administration, Oral; Aged; Arthroplasty; Body Weight; Clinical Trials as Topic; Double-Blind Method | 1977 |
14 other studies available for hydroxychloroquine and Body Weight
| Article | Year |
|---|---|
Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Body Weight; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 2023 |
Anticancer Effects of Combination of Indole-3-Carbinol and Hydroxychloroquine on Ehrlich Ascites Carcinoma via Targeting Autophagy and Apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascites; Autophagy; Body Weight; Carcinoma; Cell Line, Tu | 2022 |
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Topics: Adult; Aged; Antirheumatic Agents; Body Mass Index; Body Weight; Drug Dosage Calculations; Female; H | 2018 |
Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment.
Topics: Adult; Aged; Anti-Infective Agents; Body Mass Index; Body Weight; Doxycycline; Endocarditis, Bacteri | 2014 |
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Topics: Adult; Aged; Antirheumatic Agents; Body Weight; Case-Control Studies; Electroretinography; Female; F | 2014 |
Effects of Multi-glycosides of Tripterygium wilfordiion in the Treatment of Sjögren's Syndrome in the Non-obese Diabetic Mouse Model.
Topics: Animals; Antibodies, Antinuclear; Body Weight; CD4 Lymphocyte Count; Disease Models, Animal; Female; | 2015 |
Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Body Weight; Chromatography, High Pressure Liquid; | 2016 |
Hydroxychloroquine attenuates cigarette smoke induced autophagic signaling in the mouse ovary.
Topics: Animals; Autophagosomes; Autophagy; Beclin-1; Body Weight; Female; Hydroxychloroquine; Mice, Inbred | 2016 |
Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcón.
Topics: Adult; Antimalarials; Body Height; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; D | 2003 |
Preventive effect of Ophiopogon japonicus polysaccharides on an autoallergic mouse model for Sjogren's syndrome by regulating the Th1/Th2 cytokine imbalance.
Topics: Animals; Autoantigens; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Drinking | 2007 |
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.
Topics: Arthritis, Rheumatoid; Body Weight; Chloroquine; Drug Administration Schedule; Humans; Hydroxychloro | 1983 |
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Coronary Disease; Female; Humans; Hydroxychloroquin | 1994 |
Comment on the article by van Kerckhove et al.
Topics: Arthritis, Juvenile; Body Weight; Child; Humans; Hydroxychloroquine; Penicillamine; Time Factors | 1989 |
Two first degree relatives with dilatation of the colon due to Crohn's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Azathioprine; Body Weight; Colectomy; Colitis, Ulcer | 1973 |